Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IDEXX Laboratories SEC filings document the formal record for a Nasdaq-listed animal-health diagnostics and software company. Form 8-K reports furnish quarterly and annual financial results, operating updates and exhibits tied to the company’s CAG Diagnostics, reference laboratory and veterinary product businesses.
The company’s filings also cover governance and capital-structure matters, including definitive proxy materials, executive compensation, board composition, officer transitions, equity-award disclosures and shareholder meeting items. Other material-event reports describe credit agreement amendments and registered common stock information, providing formal disclosure on IDEXX’s financing arrangements, corporate governance and reporting obligations.
IDEXX Laboratories, Inc. announced quarterly results for the period ended September 30, 2025. The company furnished a press release as Exhibit 99.1 with additional details. The information was provided under Item 2.02 of Form 8‑K and is being furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.
IDEXX Laboratories director Karen Peacock filed an amended initial insider report to correct her stated holdings. The Form 3/A clarifies that she beneficially owns 1 share of common stock directly, which was inadvertently omitted from her original Form 3. The amendment does not reflect a new buy or sell transaction; it simply updates the ownership record.
IDEXX Laboratories (IDXX) filed a Form 3 showing initial beneficial ownership by a reporting person who is a Director. The filing reports 0 shares of Common Stock beneficially owned (Direct) and no derivative securities listed in Table II. The date of the event requiring the statement is 10/06/2025, and the form was filed by one reporting person. The submission is signed by Karen Peacock on 10/14/2025.
IDEXX Laboratories announced the election of Karen Peacock to its Board of Directors in a press release dated October 7, 2025. The election was disclosed on Form 8-K filed with the Commission and attached as Exhibit 99.1. The filing is signed by Sharon E. Underberg, Executive Vice President, General Counsel and Corporate Secretary. No additional details about director background, committee assignments, or changes to board composition were included in the filing.
Idexx Laboratories insider Form 4: Jonathan Jay Mazelsky, identified as President and CEO and a director, reported a disposal of 1,051 shares of Idexx common stock on 08/15/2025. The form shows 1,051 shares disposed and 82,443.3016 shares beneficially owned following the transaction. The filing was signed by Lily J. Lu as Attorney-in-Fact on 09/04/2025.
Martin A. Smith, Executive Vice President of IDEXX Laboratories (IDXX), reported insider transactions dated 09/01/2025. The filing shows an acquisition of 18 shares of IDEXX common stock and a disposition of 5 shares, leaving reported beneficial ownership figures of 1,438.659 and 1,433.659 shares after each transaction respectively. The filing also records 18 restricted stock units (RSUs) tied to those shares; the RSU grant vests in four annual installments beginning September 1, 2022 and represents contingent rights to one share each. The filing discloses that 28.709 shares were purchased earlier under the issuer’s Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. A price of $647.09 is shown for the disposed shares, noted as the Nasdaq closing price on August 29, 2025. The form is signed by an attorney-in-fact on behalf of Mr. Smith.
Joseph L. Hooley, a director of IDEXX Laboratories, Inc. (IDXX), reported equity awards received in connection with his board service. On 09/01/2025 he was granted 158 restricted stock units (each convertible to one share) and a non-qualified stock option to purchase 364 common shares at an exercise price of $647.09 per share. Both awards vest in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever is earlier.
These awards represent pro rata non-employee director compensation for service from his election to the board on July 10, 2025 through the 2026 annual meeting. Following the reported transactions, the reporting person beneficially owns 158 shares via RSUs and holds options on 364 shares.
M. Anne Szostak, a director of IDEXX Laboratories, reported multiple transactions on 08/22/2025. She exercised a non-qualified stock option to acquire 2,187 shares at an exercise price of $206.62 per share and, on the same date, sold 2,187 shares at a weighted average price of $647.3252 per share. She also reported two gift transactions of 259 shares each: one reducing her direct holdings and one reflecting shares held by related trusts/foundations. Following the reported transactions, the filing shows 2,449 shares held directly and identified indirect interests via a trust and a family foundation.
Idexx Laboratories (IDXX) Form 144 notice: An insider intends to sell 2,187 shares of common stock, representing an aggregate market value of $1,415,700.21, on 08/22/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were acquired the same day via stock option exercise and paid in cash. There were 80,004,694 shares outstanding reported for the issuer. The filer reports no sales in the prior three months. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Idexx Laboratories (IDXX) reporting person Michael G. Erickson sold a total of 405.892 shares on 08/12/2025 in two non-derivative transactions, at prices around $649.85 to $650.00 per share. The filing shows two S-code sales: 318 shares at $649.99 and 87.892 shares at a weighted-average price of $649.8507. Following these transactions Erickson is reported to beneficially own 11,286.97 shares (the filing also lists 11,374.862 shares following the larger sale), and the filing notes 26.4960 shares previously purchased under the Issuer Employee Stock Purchase Plan.
The Form 4 was signed by an attorney-in-fact on 08/14/2025 and includes an undertaking to provide details on the number of shares sold at each price upon request. All information here is stated explicitly in the filing.